Blood Flow Restriction Following Hip Arthroscopy

Description

This study will be a prospective randomized, double-blinded, placebo-controlled trial of patients undergoing primary hip arthroscopy for FAIS and/or labral pathology. All patients who sign the consent form will be enrolled in the study and randomized to one of the two treatment arms. Follow-up will take place at 1-month, 3-months, 6-months, and 1-year.

Conditions

Labral Tear, Glenoid, Femoral Acetabular Impingement

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will be a prospective randomized, double-blinded, placebo-controlled trial of patients undergoing primary hip arthroscopy for FAIS and/or labral pathology. All patients who sign the consent form will be enrolled in the study and randomized to one of the two treatment arms. Follow-up will take place at 1-month, 3-months, 6-months, and 1-year.

Postoperative Blood Flow Restriction Training Following Hip Arthroscopy: A Randomized Clinical Trial

Blood Flow Restriction Following Hip Arthroscopy

Condition
Labral Tear, Glenoid
Intervention / Treatment

-

Contacts and Locations

Chicago

Rush University Medical Center, Chicago, Illinois, United States, 60612

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult patients 18-40
  • * English-speaking
  • * Clinical and radiographic examination (MRI) consistent FAIS and/or labral pathology, and are schedule for primary hip arthroscopy
  • * Written and informed consent for study participation
  • * Patients younger than 18 or older than 40 years of age
  • * Non-native English speaker
  • * Revision surgery or prior history of ipsilateral hip or knee surgery
  • * Inability to comply with the proposed follow-up clinic visits
  • * Patients lacking decisional capacity
  • * Patients with a history of deep vein thrombosis, pulmonary embolism, or known clotting disorder or hypercoagulable state
  • * Pregnant or breast-feeding women. Pregnancy as determined by a positive pregnancy test prior to procedure. Females of childbearing potential must agree to use an acceptable birth control method during study participation.
  • * Worker's compensation patients
  • * Any clinically significant finding that would place the patient at health risk, impact the study, or affect the completion of the study
  • * Any psychiatric illness that would prevent comprehension of the details and nature of the study and interfere with follow-up clinic visits

Ages Eligible for Study

18 Years to 40 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Rush University Medical Center,

Jorge Chahla, MD PhD, PRINCIPAL_INVESTIGATOR, Rush University Medical Center

Study Record Dates

2026-01